State Farm Mutual Automobile Insurance Co. continued to hold its stake in Genomic Health, Inc. (NASDAQ:GHDX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 317,240 shares of the medical research company’s stock at the close of the second quarter. State Farm Mutual Automobile Insurance Co. owned approximately 0.92% of Genomic Health worth $10,326,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the stock. Columbia Wanger Asset Management LLC boosted its stake in Genomic Health by 26.1% during the first quarter. Columbia Wanger Asset Management LLC now owns 1,607,649 shares of the medical research company’s stock valued at $50,625,000 after buying an additional 332,311 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Genomic Health by 8.8% in the 1st quarter. Vanguard Group Inc. now owns 1,564,170 shares of the medical research company’s stock valued at $49,256,000 after purchasing an additional 126,807 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Genomic Health by 27.1% in the 1st quarter. Renaissance Technologies LLC now owns 733,200 shares of the medical research company’s stock valued at $23,088,000 after purchasing an additional 156,500 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in shares of Genomic Health by 10.0% in the 1st quarter. Loomis Sayles & Co. L P now owns 584,515 shares of the medical research company’s stock valued at $18,406,000 after purchasing an additional 53,344 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of Genomic Health by 3.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 497,340 shares of the medical research company’s stock valued at $16,189,000 after purchasing an additional 14,665 shares during the last quarter. 88.91% of the stock is owned by institutional investors.
In related news, CEO Kimberly J. Popovits sold 1,468 shares of the business’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $32.67, for a total transaction of $47,959.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider James J. Vaughn sold 8,000 shares of the business’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total transaction of $244,720.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,642 shares of company stock valued at $1,354,431. Insiders own 46.20% of the company’s stock.
Shares of Genomic Health, Inc. (GHDX) traded up 0.887% during mid-day trading on Friday, reaching $31.275. The company’s stock had a trading volume of 77,036 shares. The stock has a 50 day moving average of $30.93 and a 200-day moving average of $31.60. The stock’s market cap is $1.08 billion. Genomic Health, Inc. has a one year low of $26.37 and a one year high of $33.97.
Genomic Health (NASDAQ:GHDX) last released its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.02). Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The company had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. During the same period in the previous year, the firm posted ($0.18) EPS. Genomic Health’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, equities research analysts expect that Genomic Health, Inc. will post ($0.01) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was posted by BBNS and is the property of of BBNS. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/genomic-health-inc-ghdx-holdings-maintained-by-state-farm-mutual-automobile-insurance-co/1603028.html.
Several research firms have recently issued reports on GHDX. Jefferies Group LLC reaffirmed a “hold” rating and issued a $33.00 price objective on shares of Genomic Health in a research note on Thursday. Cowen and Company reiterated a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a report on Friday, September 1st. BidaskClub upgraded Genomic Health from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Canaccord Genuity reduced their price target on Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 15th. Finally, Piper Jaffray Companies reiterated a “hold” rating and issued a $31.00 price target on shares of Genomic Health in a report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $32.00.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with our FREE daily email newsletter.